This PTM-informed multimodal framework integrates routine pathology and transcriptomic data, providing robust prognostic stratification, clinically relevant immune and therapeutic phenotyping, and mechanistic insight supporting B3GNT6 as a potential therapeutic target in COAD. This evidence concerns the gene B3GNT6 and colon adenocarcinoma.